HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Comparative tolerability: fulvestrant, L‑acestrant, capivasertib
Hamilton quantifies discontinuation rates and toxicity risk profiles across these endocrine and targeted options.
Play episode from 43:30
Transcript
